We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Lop off zeros

8 April 2014 By Robert Cyran

Japan’s Takeda and its diabetes drug partner Eli Lilly were ordered to pay the 10-figure sum for covering up cancer risks. Whopping fines are common in the high-risk world of pharmaceuticals. Past cases and judicial guidance, however, suggest that this one may go too far.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)